BioCad

15 articles about BioCad

• BIOCAD and SPH Agree to Build a Drug Substance Manufacturing Facility in China

  9/12/2018

  BioCad and Shanghai Pharmaceutical Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People's Republic of China.

• BIOCAD Demonstrated the Use of Hela Cells in Oncology Research

  12/8/2017

  BioCad demonstrated how "immortal" HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs.

• Russian Biotechnology Company BIOCAD Prepares to Enters the European Market

  10/25/2017

  The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines.

• BioCad’s Rituximab Biosimilar To Receive MA Soon In India

  7/5/2017

• BioCad Registered The First Rituximab Biosimilar In Bolivia And Honduras

  6/5/2017

• BioCad Joins The EU

  5/25/2017

• BioCad Keeps On Supplying Its Medicine For Blood Cancer Treatment In Vietnam

  3/30/2017

• BioCad: The First Ever Biosimilar Of Interferon Beta-1a Approved In Russia

  3/6/2017

• BioCad: Advanced Rheumatoid Arthritis Medicine Developed In Russia

  7/11/2016

• BioCad Started Exports Of Pharmaceuticals To Sri Lanka

  3/30/2016

• BioCad Release: Innovative Russian Medicine Mobilizes Human Immune System To Fight Cancer

  3/23/2016

• BioCad Scores Another Victory In mAb Biosimilars With Marketing Authorization For Bevacizumab

  12/10/2015

• BioCad Release: Russian Biotechnological Company Won The Case Against Big Pharma On The Patent Dispute Notable For The Pharmaceutical Industry

  11/3/2015

• Amgen, Pfizer Inc. Duke it Out for Takeover of BioCad, Deal May Top $1 Billion

  6/28/2013

• Nobel Biocare Acquires BioCad -- a Leading Developer of Computer-aided Design Software for Prosthetics for EUR 26 Million

  11/11/2008